2009

Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia

Top

Ikramuddin S, Korner J, Lee W-J, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia. JAMA. 2013;309(21):2240-2249.

Use of a active drug safety surveillance system to assess the risk of acute pancreatitis w/ exenatide or sitagliptin compared to metformin or glyburide

Top

Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25(4):1019-1027. To estimate risk and relative risk (RR) of acute pancreatitis among patients using incretin-based diabetes therapies (exenatide or sitagliptin) compared to patients treated with agents with established safety profiles (metformin or glyburide).

Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study

Top

Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia. 2009 Mar 12. [Epub ahead of print]. Diabetes has been related to Alzheimer's disease with inconsistent findings. We aimed to clarify the association of diabetes with different dementing disorders taking into account glycaemic control, and to explore the link between glucose dysregulation and neurodegeneration.

Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis

Top

Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373(9677):1773-1779. Women with gestational diabetes are at increased risk of developing type 2 diabetes, but the risk and time of onset have not been fully quantified. We therefore did a comprehensive systematic review and meta-analysis to assess the strength of association between these conditions and the effect of factors that might modify the risk.

Two risk-scoring systems for predicting incident diabetes mellitus in U.S. adults age 45 to 64 years

Top

Kahn HS, Cheng YJ, Thompson TJ, Imperatore G, Gregg EW. Two risk-scoring systems for predicting incident diabetes mellitus in U.S. adults age 45 to 64 years. Ann Intern Med. 2009;150(11):741-751. Simple prediction scores could help identify adults at high risk for diabetes.

Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists

Top

Hansen KB, Knop FK, Holst JJ, Vilsbøll T. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Int J Clin Pract. 2009;63(8):1154-1160. The incretin system is an area of great interest for the development of new therapies for the management of type 2 diabetes. Existing antidiabetic drugs are often insufficient at getting patients to glycaemic goals.

Treating type 2 diabetes: how safe are current therapeutic agents?

Top

Philippe J, Raccah D. Treating type 2 diabetes: how safe are current therapeutic agents?. Int J Clin Pract. 2009;63(2):321-332. Sulphonylureas (SUs) and biguanides (metformin) are the current mainstays in the treatment of type 2 diabetes (T2DM) and represent the most commonly used oral hypoglycaemic agents (OHAs).

Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study

Top

Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Diabetes Care. 2009;373(9682):2215-2221. Pioglitazone (PIO), a thiazolidinedione (TZD), is reported to be highly effective in the treatment of type 2 diabetes mellitus, but is associated with edema, heart failure, and weight gain. This study documented long-term tolerability outcomes of patients taking pioglitazone and assessed how troublesome these adverse events were for the patients.

Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients w type 2 diabetes mellitus treated w pioglitazone

Top

Grossman LD, Parlan G, Bailey AL, Yee G, Yu M, Chan JY.. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years. Clin Ther.. 2009;31(1):74-88. Pioglitazone (PIO), a thiazolidinedione (TZD), is reported to be highly effective in the treatment of type 2 diabetes mellitus, but is associated with edema, heart failure, and weight gain. This study documented long-term tolerability outcomes of patients taking pioglitazone and assessed how troublesome these adverse events were for the patients.

The role of pioglitazone in modifying the atherogenic lipoprotein profile

Top

Hanefeld M. The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes, Obesity and Metabolism. 2009;11(8):742-756. Pioglitazone, a thiazolidinedione, has established efficacy in improving glycaemic control in patients with type 2 diabetes. Pioglitazone also improves components of the mixed dyslipidaemia profile common in these patients, as typified by raised levels of plasma triglycerides, low levels of HDL cholesterol (HDL-C) and a raised proportion of LDL cholesterol (LDL-C) occurring as the small dense subfraction.

1 2 3 4 5 6 7 8 Next